the aims of this article are to provide an overview of the current status of the aforementioned programs and to provide an overview of the current status of our lead drug, b-729, and its clinical development and financial updates. we will also provide an overview of the current status of the clinical trial and the current status of the clinical trial. we will also provide an overview of our current progress on the development of a new combination therapy for chronic hepatitis b and to provide an overview of the current progress in our research and research efforts.